Institutional Registry of Haemorrhagic Hereditary Telangiectasia
The purpose of this study is to create an institutional and population-based registry of Haemorrhagic Hereditary Telangiectasia with a prospective survey based on epidemiological data, risk factors, diagnosis, prognosis, treatment, monitoring and survival.
This study will also describe the occurrence of Haemorrhagic Hereditary Telangiectasia in the population of HIBA in the Central Hospital, as well as the characteristics of clinical presentation and evolution.
Haemorrhagic Hereditary Telangiectasia
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Institutional Registry of Haemorrhagic Hereditary Telangiectasia|
- morbidity [ Time Frame: 1 year ]Control visit every three month
|Study Start Date:||June 2012|
|Estimated Study Completion Date:||December 2017|
|Estimated Primary Completion Date:||June 2017 (Final data collection date for primary outcome measure)|
Haemorrhagic Hereditary Telangiectasia is a uncommon autosomic hereditary disorder caracterizad for recurrent epistaxis,cutaneomucous telangiectasias and arteriovenous malformations in diferent organs; brain, lung, liver and gastrointestinal are more often afected . Afect one in 5000-8000 individual in worldwide. HHT may produce important morbidity like brain absces, stroke, hemoptisis and cronic ferropenic anemia.
Molecular mechanism of this disorder are complex and still no fully dilucidated. The genes mutated in HHT encode endothelial cell-expressed proteins that mediate signalling by the transforming growth factor (TGF)b superfamily. Endoglin (HHT type I) and ACVRL-1 (HHT type 2) mutations are responsible in more than 80% of the individuals. Mutation of SMAD 4 protein (MADH4)cause HHT in association with juvenile polyposis. HHT may associated with primary pulmonary hypertension en more rare cases.
There arent HHT register in Argentina and Latinamerican population. This registry may gader valious information in order to generate a better diagnosis and treatment of our population and others.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01761981
|Contact: Marcelo M Serra, MD||+541149590200 ext email@example.com|
|Contact: Diego H Giunta, MD||+541149590200 ext firstname.lastname@example.org|
|Hospital Italiano de Buenos Aires||Recruiting|
|Buenos Aires, Argentina, 1081|
|Contact: Marcelo M Serra, MD +541149590200 ext 4419 email@example.com|
|Contact: Diego H Giunta, MD +541149590200 ext 4419 firstname.lastname@example.org|
|Principal Investigator:||Marcelo M Serra, MD||HHT Center of Excelence Hospital Italiano de Buenos Aires|